217.5403 Eligibility requirements for treatment with investigational drug, biological product, or device.

A patient shall be eligible for treatment with an investigational drug, biological product, or device if the patient has:

(1) A terminal illness that is attested to by the patient's treating health care provider;

(2) Considered all other treatment options currently approved by the United States Food and Drug Administration;

(3) Received a recommendation from the patient's treating health care provider for an investigational drug, biological product, or device;

(4) Given written informed consent for the use of the investigational drug, biological product, or device; and

(5) Documentation from the treating health care provider that the patient meets the requirements of this section.

Effective: June 29, 2017

History: Created 2017 Ky. Acts ch. 65, sec. 3, effective June 29, 2017.

Formerly codified as KRS 217.5405.